Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Strengths
  • Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 39% by 2022.
  • The company returns high margins, thereby supporting business profitability.
  • The stock is in a well-established, long-term rising trend above the technical support level at 7690 GBX
Weaknesses
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • With an expected P/E ratio at 38.85 and 27.92 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
ASTRAZENECA PLC11.34%145 125
JOHNSON & JOHNSON1.87%391 238
ROCHE HOLDING AG0.06%294 334
PFIZER, INC.-1.86%213 662
MERCK & CO., INC.-10.92%204 919
NOVARTIS AG-17.85%182 240
ABBVIE INC.4.95%163 988
NOVO NORDISK A/S5.20%150 040
AMGEN INC.-0.16%140 971
ELI LILLY AND COMPANY16.36%138 627
BRISTOL-MYERS SQUIBB COMPAN..-4.94%137 535
SANOFI-2.50%129 396
GLAXOSMITHKLINE PLC-12.58%101 059
CHUGAI PHARMACEUTICAL CO., ..43.57%74 916
JIANGSU HENGRUI MEDICINE CO..25.05%69 163
BAYER AG-23.13%64 812
More Results
Financials (USD)
Sales 2020 26 712 M - -
Net income 2020 3 067 M - -
Net Debt 2020 13 578 M - -
P/E ratio 2020 50,7x
Yield 2020 2,54%
Capitalization 145 B 145 B -
EV / Sales 2020 5,94x
EV / Sales 2021 5,21x
Nbr of Employees 70 600
Free-Float 95,7%
Upcoming event on ASTRAZENECA PLC
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes